2018 - Fellow, National Academy of Inventors
Internal medicine and Carcinoma are frequently intertwined in his study. He integrates Carcinoma and Breast cancer in his studies. Louis M. Weiner performs integrative study on Breast cancer and Survival rate in his works. His multidisciplinary approach integrates Survival rate and Cancer in his work. Louis M. Weiner frequently studies issues relating to Cancer therapy and Cancer. Cancer therapy is frequently linked to Internal medicine in his study. With his scientific publications, his incorporates both Immune system and Cancer cell. Louis M. Weiner undertakes interdisciplinary study in the fields of Cancer cell and Immune system through his research. As part of his studies on Immunology, Louis M. Weiner often connects relevant subjects like CD3.
Louis M. Weiner is involved in relevant fields of research such as Perioperative and Chemoradiotherapy in the realm of Surgery. He connects Perioperative with Surgery in his study. His Internal medicine study often links to related topics such as Carcinoma. Many of his studies on Carcinoma involve topics that are commonly interrelated, such as Internal medicine. In his work, he performs multidisciplinary research in Immunology and Cytokine. He combines Immune system and Immunotherapy in his research. He combines Immunotherapy and Immune system in his research. He performs multidisciplinary study in Demography and Gerontology in his work. He conducts interdisciplinary study in the fields of Gerontology and Demography through his research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Monoclonal antibody therapy of cancer
Gregory P Adams;Louis M Weiner.
Nature Biotechnology (2005)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever;Martin A. Cheever;James P. Allison;Andrea S. Ferris;Olivera J. Finn.
Clinical Cancer Research (2009)
Monoclonal antibodies: versatile platforms for cancer immunotherapy.
Louis M. Weiner;Rishi Surana;Shangzi Wang.
Nature Reviews Immunology (2010)
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
Gregory P. Adams;Robert Schier;Adrian M. McCall;Heidi H. Simmons.
Cancer Research (2001)
Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site
Robert Schier;Adrian McCall;Gregory P. Adams;Keith W. Marshall.
Journal of Molecular Biology (1996)
Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival
Adam C. Berger;Jeffrey Farma;Walter J. Scott;Gary Freedman.
Journal of Clinical Oncology (2005)
Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.
Robert Schier;Jacqueline Bye;Gerald Apell;Adrian McCall.
Journal of Molecular Biology (1996)
Highly Specific in Vivo Tumor Targeting by Monovalent and Divalent Forms of 741F8 Anti-c-erbB-2 Single-Chain Fv
Gregory P. Adams;John E. McCartney;Mei-Sheng Tai;Hermann Oppermann.
Cancer Research (1993)
Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies
Gregory P. Adams;Robert Schier;Keith Marshall;Ellen J. Wolf.
Cancer Research (1998)
Monoclonal antibody therapy for cancer.
Margaret von Mehren;Gregory P. Adams;Louis M. Weiner.
Annual Review of Medicine (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: